Opna Bio Announces Fast Track Designation Granted to OPN-6602 for the Treatment of Multiple Myeloma

OPN-6602 Currently Treating Patients in Phase 1 Clinical Trial SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 15, 2026-- Opna Bio, a clinical-s ...
Seeking Alpha

Foghorn Therapeutics to Present Preclinical Data from Its Selective CBP and EP300 Protein Degrader Programs and Preclinical Data for FHD-286, a Potent, Selective Inhibitor of ...

CAMBRIDGE, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases ...
Targeted Oncology

FDA Grants Fast Track Designation to OPN-6602 for Multiple Myeloma

The FDA has granted fast track designation to OPN-6602, an investigational oral dual inhibitor of EP300 and CREB-binding ...
Seeking Alpha

Foghorn Therapeutics Inc. (FHTX) Discusses Pipeline Updates for Selective ARID1B, CBP and EP300 Degrader Programs Transcript

Welcome to the Foghorn Pipeline Update Conference Call. [Operator Instructions] As a reminder, this webcast is being recorded today, October 30, 2025. I will now turn the call over to Karin Hellsvik, ...
Business Wire

Opna Bio Receives Orphan Drug Designation for OPN-6602, an Oral EP300/CBP Bromodomain Inhibitor, for Multiple Myeloma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Opna Bio, a clinical-stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics, announced today that the FDA ...
Nasdaq

Foghorn Therapeutics Advances FHD-909 in Phase 1 Trial for SMARCA4 Mutated Cancers with Promising Preclinical Data for Combination Therapies

Foghorn Therapeutics Inc. announced advancements in their clinical and preclinical programs, focusing on FHD-909 (LY4050784), a selective SMARCA2 inhibitor currently in a Phase 1 trial targeting ...
Business Insider

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors - ...